16/05/2024  13:57:16 Chg. -0.34 Volume Bid03:01:16 Demandez à03:01:16 Capitalisation boursière Dividende Y. Rapport P/E
149.76EUR -0.23% 5
Chiffrre d'affaires: 756.90
-Bid taille: - -Ask la taille: - 267.08 Mrd.EUR - -

Description de l'entreprise

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
 

Conseil d'administration & Conseil de surveillance

PDG
Richard A. Gonzalez
Conseil d'administration
Scott T. Reents, Carrie Strom, Dr. Azita Saleki-Gerhardt, Jeffrey R. Stewart, Perry C. Siatis, Rae L. Livingston, Robert A. Michael, Timothy J. Richmond, Kevin Buckbee, Nicholas Donoghoe, Tracie Haas, Thomas Hudson, Greg Miley, Elaine K. Sorg
Conseil de surveillance
Richard A. Gonzalez, Brett J. Hart, Edward J. Rapp, Frederick H. Waddell, Glenn F. Tilton, Melody B. Meyer, Rebecca B. Roberts, Robert J. Alpern, Roxanne S. Austin, Thomas Freyman, William H.L. Burnside
 

Données de l'entreprise

Nom: AbbVie Inc.
Adresse: 1 North Waukegan Road,North Chicago, Illinois 60064-6400, USA
Téléphone: +1-847-932-7900
Fax: -
Courriel: -
Internet: www.abbvie.com/
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: Pharmaceuticals
Fin de l'exercice financier: 31/12
Flotte libre: 96.70%
IPO date: 02/01/2013

Relations avec les investisseurs

Nom: Liz Shea
Téléphone IR: +1-847-935-2211
IR-Fax: -
E-mail IR: liz.shea@abbvie.com

Principaux actionnaires

Autres
 
64.91%
Vanguard Group Inc
 
9.03%
Blackrock Inc.
 
7.88%
State Street Corporation
 
4.43%
JP Morgan Chase & Company
 
3.22%
Capital International Investors
 
2.44%
Geode Capital Management, LLC
 
1.98%
Capital Research Global Investors
 
1.84%
Morgan Stanley
 
1.77%
Autres
 
2.50%